Frequently asked questions
In 2022, the global Conjugate Vaccines Market is expected to be worth USD 18154.5million.
The Conjugate Vaccines Market is estimated to increase at a CAGR of 10.00% between 2023 and 2030, reaching USD 38915.7 Million in 2030.
In 2022, Multivalent Conjugate Vaccines have the largest market share.
The Pediatric Population drives market demand
The adult market will also accelerate, but children will have the highest CAGR.
North America would account for 35% of the total market in 2022
The top players include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech
Raising awareness of the need of bacterial infection vaccine Advances in vaccination technology that result in better efficacy and safety Growing government initiatives and immunization programs to avoid infectious diseases are the primary market drivers.
High costs involved with the research and production of conjugate vaccines, stringent regulatory criteria for vaccine approval and market entrance, and limited accessibility and affordability of vaccinations in particular locations are market restraints.
The key market opportunity is the expansion of the market in emerging economies with growing healthcare infrastructure, the development of conjugate vaccines for new target diseases and age groups, and collaboration and partnerships among pharmaceutical companies to enhance research and development efforts.